The current prevalence of chronic obstructive pulmonary disease (COPD) in France is estimated to be 2.6 million and is predicted to increase to 2.8 million by 2025. Presently, there is a lack of data ...on COPD management within the private healthcare setting. The aim of this study was to investigate the management of COPD exacerbations by pulmonologists within private practices in France.
A prospective, online, qualitative survey was distributed to private practice pulmonologists in France. The survey covered all aspects of COPD management from diagnosis and therapeutic management, to secondary prevention and organization of care. Survey responses were collected between 27 January 2018 and 18 June 2018 and all data were summarized descriptively.
The survey had a response rate of 20.6%, with 116 out of 563 pulmonologists providing responses. Overall, 87.4% of respondents stated that the management of COPD represented over 15% of their total clinical activity. Most respondents indicated that they work closely with general practitioners and a large multidisciplinary team to manage patients with numerous comorbidities. Following a COPD exacerbation, the majority of respondents (78.4%) were in favor of using respiratory-connected devices (class 2a-connected medical device according to the French HAS classification and available on medical prescription) to assist with patient follow-up at home.
COPD management forms part of the core clinical activity for pulmonologists within the private practice setting in France. Patients with COPD generally have multiple comorbidities and are managed by a multidisciplinary team in line with French guidelines. The use of respiratory-connected devices was highlighted as an important new strategy for improving patient care following a COPD exacerbation.
Usure urbaine 2 Anne Compagnon
EspacesTemps.net,
01/2006
Journal Article
Recenzirano
Odprti dostop
Avenue Bizot, 12 e arrondissement à Paris. Un trottoir après une averse. Les habitants des immeubles alentours et les clients des petits commerces ont pour habitude de parquer leurs motos ou vespas à ...cet endroit précis. Au fil des jours, les pieds des engins ont formé de petits creux dans le revêtement du trottoir. L’air de rien, les jours ordinaires des citadins usent la ville. « Photographier, c’est conférer de l’importance » (Sontag, 2000, p. 45). En pointant mon ...
Rue du Faubourg St-Antoine, à Paris, un matin vers 10 heures. Les balayeurs ont ouvert les vannes au bord de la chaussée. Une flaque s’est formée, les passants ont laissé les empreintes de leurs ...semelles sur le trottoir. Circulez, rien à signaler. Image fixe d’un événement éphémère. Instantané sur lequel on lit le mouvement du flux piétonnier. L’usage d’un appareil photos quand on arpente la ville, peut rendre sensible aux détails révélateurs de l’urbanité. C’est ce ...
Background: Single doses of zafirlukast attenuate exercise-induced bronchoconstriction (EIB), but previous studies have not measured zafirlukast’s effects after regular dosing or its duration of ...effect beyond 4 hours.
Objective: The purpose of this study was to assess the effects of zafirlukast 20 mg and 80 mg twice daily compared with placebo on exercise challenges performed at 2 and 8 hours after the last dose of regular administration.
Methods: Twenty-four adult patients with stable asthma taking β
2-agonists, inhaled corticosteroids, or both received treatment with zafirlukast (20 mg and 80 mg) and placebo. The patients were treated twice daily for 14 days in a randomized, double-blind, 3-way cross-over fashion, with a 7-day washout period between each treatment. Exercise challenges were performed at 2 and 8 hours after the morning dose on day 14. FEV
1 was measured before exercise and at set intervals after exercise until it returned to within 7% of its baseline value.
Results: Both zafirlukast treatments significantly reduced EIB, as measured by the area under the FEV
1 time curve after the 2-hour (
P < .001) and 8-hour (
P < .001) exercise challenges and maximum fall in FEV
1 at the 2-hour challenge (
P < .001). The comparison at 8 hours between treatments was affected by the unexpected finding that EIB was less in the placebo group after the 8-hour challenge than after the 2-hour challenge, as measured by the within-group change in the maximum fall in FEV
1 (
P < .001) and the area under the FEV
1 time curve (
P = .0023).
Conclusion: Regular zafirlukast treatment protects against EIB for at least 8 hours after regular dosing. A refractory period, which may be caused by exercise-induced leukotriene release, may last for up to 6 hours after the initial response to exercise. (J Allergy Clin Immunol 1999;1155-61.)
PDF
